Skip to content Skip to sidebar Skip to footer

AbbVie

AbbVie to Develop mRNA Modulators Using Anima Biotech Platform

AbbVie has agreed to discover and develop mRNA biology modulators for three targets in oncology and immunology by applying Anima Biotech’s mRNA Lightning platform, through an up to $582 million collaboration announced by the companies. In return, Anima—an mRNA-based drug developer based in Bernardsville, NJ—has granted AbbVie exclusive rights to license and further develop and…

Read More

AbbVie and Anima Biotech pair up on discovery and development of mRNA Biology Modulators

Anima will use its mRNA Lightning platform to discover novel mRNA biology modulators against the collaboration targets: providing AbbVie exclusive rights to license and further develop and commercialize the programs. Anima will receive an upfront payment of $42m and may be eligible to receive up to $540m in option fees and R&D milestones across the three targets,…

Read More